Supplements That Help With Wegovy (Semaglutide 2.4 mg) Nausea: What the Evidence Actually Shows

What the Wegovy label records

The label's safety data for the 2.4 mg weekly injection pool three placebo-controlled trials in 2,116 adults with obesity or overweight and 1,261 on placebo, treated for up to 68 weeks. Nausea occurred in 44% versus 16% and vomiting in 24% versus 6%; any gastrointestinal reaction was reported by 73% versus 47% [1].

In the pooled trials, 1.8% of adults taking Wegovy and 0.2% taking placebo stopped treatment because of nausea [1].

The label steps the dose up every four weeks: 0.25 mg for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg, with maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg [1].

Ginger

Ginger has been studied for nausea after surgery and in other settings, but not with Wegovy. A systematic review summarized six randomized trials. Three were in postoperative nausea, and two of those suggested ginger was better than placebo and about as effective as metoclopramide. Pooled across the postoperative trials, 1 g of ginger taken before surgery did not reduce the incidence of postoperative nausea significantly (absolute risk reduction 0.052, 95% CI -0.082 to 0.186). Single trials in seasickness, morning sickness and chemotherapy-induced nausea favored ginger over placebo [2].

Peppermint oil

One small report looked at inhaled peppermint oil for nausea after cardiac surgery: of 123 patients who consented, 34 (28%) developed nausea and were offered a nasal inhaler containing peppermint oil, and average ratings fell from 3.29 to 1.44 on a 0 to 5 scale within two minutes. The report compared ratings before and after and had no comparison group, and it was not done in people taking Wegovy [3].

What the label flags instead

The label lists serious gastrointestinal risks alongside ordinary nausea. Acute pancreatitis has been observed with GLP-1 receptor agonists including Wegovy; the label describes persistent severe abdominal pain, sometimes radiating to the back, that may or may not be accompanied by nausea or vomiting, and says Wegovy should promptly be discontinued if pancreatitis is suspected. Acute gallbladder disease is also listed, with cholelithiasis in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2% in adult weight-reduction trials [1].